Publications
Click here for a full PubMed Search on Young Lab publications.
Selected References
1. Young VB. Unexpected Results From a Phase 2 Trial of a Microbiome Therapeutic for Clostridioides difficile Infection: Lessons for the Future. Clin Infect Dis. 2021;72(12):2141-3. Epub 2020/04/25. doi: 10.1093/cid/ciaa476. PubMed PMID: 32330238; PMCID: PMC8204768.2. Ranallo RT, Clifford McDonald L, Laufer Halpin A, Hiltke T, Young VB. The State of Microbiome Science at the Intersection of Infectious Diseases and Antimicrobial Resistance. J Infect Dis. 2021. Epub 2021/03/06. doi: 10.1093/infdis/jiab020. PubMed PMID: 33667294.3. Miles-Jay A, Young VB, Pamer EG, Savidge TC, Kamboj M, Garey KW, Snitkin ES. A multisite genomic epidemiology study of Clostridioides difficile infections in the USA supports differential roles of healthcare versus community spread for two common strains. Microb Genom. 2021;7(6). Epub 2021/06/29. doi: 10.1099/mgen.0.000590. PubMed PMID: 34180789; PMCID: PMC8461479.4. Leslie JL, Jenior ML, Vendrov KC, Standke AK, Barron MR, O'Brien TJ, Unverdorben L, Thaprawat P, Bergin IL, Schloss PD, Young VB. Protection from lethal Clostridioides difficile infection via intraspecies competition for cogerminant. mBio. 2021;12(2). Epub 2021/04/01. doi: 10.1128/mBio.00522-21. PubMed PMID: 33785619; PMCID: PMC8092246.5. Abernathy-Close L, Barron MR, George JM, Dieterle MG, Vendrov KC, Bergin IL, Young VB. Intestinal Inflammation and Altered Gut Microbiota Associated with Inflammatory Bowel Disease Render Mice Susceptible to Clostridioides difficile Colonization and Infection. mBio. 2021;12(3):e0273320. Epub 2021/06/16. doi: 10.1128/mBio.02733-20. PubMed PMID: 34126769.6. Schnizlein MK, Vendrov KC, Edwards SJ, Martens EC, Young VB. Dietary Xanthan Gum Alters Antibiotic Efficacy against the Murine Gut Microbiota and Attenuates Clostridioides difficile Colonization. mSphere. 2020;5(1). Epub 2020/01/10. doi: 10.1128/mSphere.00708-19. PubMed PMID: 31915217; PMCID: PMC6952194.7. Ransom EM, Burnham CD, Jones L, Kraft CS, McDonald LC, Reinink AR, Young VB. Fecal Microbiota Transplantations: Where Are We, Where Are We Going, and What Is the Role of the Clinical Laboratory? Clin Chem. 2020;66(4):512-7. Epub 2020/04/02. doi: 10.1093/clinchem/hvaa021. PubMed PMID: 32232453.8. Nagao-Kitamoto H, Leslie JL, Kitamoto S, Jin C, Thomsson KA, Gillilland MG, 3rd, Kuffa P, Goto Y, Jenq RR, Ishii C, Hirayama A, Seekatz AM, Martens EC, Eaton KA, Kao JY, Fukuda S, Higgins PDR, Karlsson NG, Young VB, Kamada N. Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. Nat Med. 2020;26(4):608-17. Epub 2020/02/19. doi: 10.1038/s41591-020-0764-0. PubMed PMID: 32066975; PMCID: PMC7160049.9. Dieterle MG, Putler R, Perry DA, Menon A, Abernathy-Close L, Perlman NS, Penkevich A, Standke A, Keidan M, Vendrov KC, Bergin IL, Young VB, Rao K. Systemic inflammatory mediators are effective biomarkers for predicting adverse outcomes in Clostridioides difficile infection. mBio. 2020;11(3). Epub 2020/05/07. doi: 10.1128/mBio.00180-20. PubMed PMID: 32371595; PMCID: PMC7403776.10. Barron MR, Cieza RJ, Hill DR, Huang S, Yadagiri VK, Spence JR, Young VB. The Lumen of Human Intestinal Organoids Poses Greater Stress to Bacteria Compared to the Germ-Free Mouse Intestine: Escherichia coli Deficient in RpoS as a Colonization Probe. mSphere. 2020;5(6). Epub 2020/11/13. doi: 10.1128/mSphere.00777-20. PubMed PMID: 33177212; PMCID: PMC7657587.